Serina Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2019 to Q2 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Serina Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2019 to Q2 2025.
  • Serina Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2025 was -415 %, a 554% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2025 -415 -351 -554% Jun 30, 2025
Q1 2025 -215 -147 -217% Mar 31, 2025
Q4 2024 -206 -142 -221% Dec 31, 2024
Q3 2024 -102 -28.4 -38.3% Sep 30, 2024
Q2 2024 -63.4 +30.9 +32.8% Jun 30, 2024
Q1 2024 -67.8 +16.5 +19.5% Mar 31, 2024
Q4 2023 -64.2 +23.2 +26.5% Dec 31, 2023
Q3 2023 -74.1 +46.5 +38.6% Sep 30, 2023
Q2 2023 -94.3 +29.5 +23.8% Jun 30, 2023
Q1 2023 -84.2 +42.3 +33.4% Mar 31, 2023
Q4 2022 -87.4 +44.3 +33.7% Dec 31, 2022
Q3 2022 -121 +21.9 +15.3% Sep 30, 2022
Q2 2022 -124 +38.2 +23.6% Jun 30, 2022
Q1 2022 -126 +67 +34.6% Mar 31, 2022
Q4 2021 -132 +116 +46.8% Dec 31, 2021
Q3 2021 -142 +402 +73.8% Sep 30, 2021
Q2 2021 -162 -767 -127% Jun 30, 2021
Q1 2021 -193 -324 -248% Mar 31, 2021
Q4 2020 -248 -306 -524% Dec 31, 2020
Q3 2020 -544 -583 -1500% Sep 30, 2020
Q2 2020 605 Jun 30, 2020
Q1 2020 130 Mar 31, 2020
Q4 2019 58.4 Dec 31, 2019
Q3 2019 38.9 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.